Skip to main content
. 2020 Jun 9;296(2):370–378. doi: 10.1148/radiol.2020192828

Figure 2a:

False-positive findings at zirconium 89 (89Zr)-pertuzumab PET/CT in a 47-year-old woman with human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer. HER2 immunohistochemistry of the primary breast malignancy was 1+ (not shown), consistent with HER2-negative malignancy. (a) Maximum intensity projection image from research 89Zr-pertuzumab PET/CT demonstrates osseous foci in the right pelvis (arrows on osseous lesions; standardized uptake values, 13.8 and 11.9), suspicious for HER2-positive malignancy. (b) Axial CT and fused 89Zr-pertuzumab PET/CT images acquired from a PET/CT-guided biopsy of an 89Zr-pertuzumab–avid osseous focus (arrow). Pathologic analysis demonstrated HER2 immunohistochemistry 2+ and FISH 1.4 (not shown), consistent with HER2-negative disease.

False-positive findings at zirconium 89 (89Zr)-pertuzumab PET/CT in a 47-year-old woman with human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer. HER2 immunohistochemistry of the primary breast malignancy was 1+ (not shown), consistent with HER2-negative malignancy. (a) Maximum intensity projection image from research 89Zr-pertuzumab PET/CT demonstrates osseous foci in the right pelvis (arrows on osseous lesions; standardized uptake values, 13.8 and 11.9), suspicious for HER2-positive malignancy. (b) Axial CT and fused 89Zr-pertuzumab PET/CT images acquired from a PET/CT-guided biopsy of an 89Zr-pertuzumab–avid osseous focus (arrow). Pathologic analysis demonstrated HER2 immunohistochemistry 2+ and FISH 1.4 (not shown), consistent with HER2-negative disease.